ArticleNature communications2023
Long-term measles antibody profiles following different vaccine schedules in China, a longitudinal study.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Epidemic risks of measles and rubella in China: a systematic review and meta-analysis.World journal of pediatrics : WJP · 2024Pooled it
- Comparative analysis of immunogenicity of Chinese MMR and MR vaccines following primary vaccination in infants in Gansu Province.Scientific reports · 2026Trial
- Protective antibody response following two doses of measles vaccination and factors for non-response among children from tribal Odisha, India.The Indian journal of medical research · 2026Article
- Serological Susceptibility to Measles Among International Students in South Korea After a Cluster of Cases: A Cross-Sectional Study.Tropical medicine and infectious disease · 2026Article
- Decreasing Antibody Titers and the Slow Decay of Measles Immunity in Mexico's Current Epidemiological Landscape.Vaccines · 2026Article
- Waning of vaccine-induced measles antibodies and population immunity gaps in the post-elimination era: a multicenter seroepidemiological study in China.Frontiers in immunology · 2026Article
- Re-Evaluating global measles management: lessons from the 2026 Bangladesh outbreak.Le infezioni in medicina · 2026Article
- Evaluation of Measles Vaccine Immunogenicity and Durability Using A Pseudotyped Virus Neutralization Assay.China CDC weekly · 2025Article
- Comparative Analysis of Long-Term Measles Immune Response After Natural Infection and Routine Vaccination in China.Vaccines · 2025Article
- Measles Population Immunity in Hunan, China: A Serological Assessment.Open forum infectious diseases · 2025Article
- Time trend of measles burden on children and adolescents in BRICS-plus countries from 1990 to 2021 and prediction to 2032.Frontiers in microbiology · 2025Article
- Low IgG Seroconversion among Persons Vaccinated against Measles, Republic of Congo.Emerging infectious diseases · 2025Article
- Low Rates of Immunity among Medical Students and Residents in the Era of the Resurgence of Measles.Pathogens (Basel, Switzerland) · 2024Article
- Hospital-acquired infections and unvaccinated children due to chronic diseases: an investigation of the 2017-2019 measles outbreak in the northern region of Vietnam.BMC infectious diseases · 2024Article
- The Problem with Delaying Measles Elimination.Vaccines · 2024Review
- Dynamics of measles immunity from birth and following vaccination.Nature microbiology · 2024Article
- Maternal antibody level, sex and birth route drive individual measles immunity differences.Nature microbiology · 2024Article
- Advancements in Vaccine Strategies for Chronic Liver Disease Patients: Navigating Post-COVID Challenges and Opportunities.Vaccines · 2024Review
- Antibody Profiling of Microbial Antigens in the Blood of COVID-19 mRNA Vaccine Recipients Using Microbial Protein Microarrays.Vaccines · 2023Article
- Measles Immunity Status of Greek Population after the Outbreak in 2017-2018: Results from a Seroprevalence National Survey.Vaccines · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Characterizing the long-term kinetics of maternally derived and vaccine-induced measles immunity is critical for informing measles immunization strategies moving forward. Based on two prospective cohorts of children in China, we estimate that maternally derived immunity against measles persists for 2.4 months. Following two-dose series of measles-containing vaccine (MCV) at 8 and 18 months of age, the immune protection against measles is not lifelong, and antibody concentrations are extrapolated to fall below the protective threshold of 200 mIU/ml at 14.3 years. A catch-up MCV dose in addition to the routine doses between 8 months and 5 years reduce the cumulative incidence of seroreversion by 79.3-88.7% by the age of 6 years. Our findings also support a good immune response after the first MCV vaccination at 8 months. These findings, coupled with the effectiveness of a catch-up dose in addition to the routine doses, could be instrumental to relevant stakeholders when planning routine immunization schedules and supplemental immunization activities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.